| Previous close | 6.20 |
| Open | 7.14 |
| Bid | 6.15 |
| Ask | 7.75 |
| Strike | 51.00 |
| Expiry date | 2024-05-24 |
| Day's range | 6.20 - 7.14 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
UPDATE 2-US FDA approves expanded use of Bristol Myers' cancer cell therapy
The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular lymphoma, that has returned or has not responded to prior treatments. The Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat patients with the type of blood cancer who have received two or more prior lines of therapy. Breyanzi was first approved in the United States in 2021 as a second-line treatment for a type of blood cancer known as large B-cell lymphoma.
ZacksBristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Barrons.comThese Stocks Moved the Most Today: GameStop, AMC, Arm, Squarespace, Walgreens, Tesla, Intel, Apple, and More
GameStop shares continue their surge in May, a report says Arm Holdings seeks to launch its first artificial-intelligence chips next year, and Squarespace is being taken private in a deal valued at $6.9 billion.
